Veeva Systems

Veeva Systems beat expectations in the second quarter: revenue rose 18% to $928 million, subscriptions increased 16%, and adjusted earnings per share were $2.35. Management raised the full-year forecast and now expects up to $3.687 billion in revenue and earnings per share of around $9.21. The Vault CRM solution and AI agents were cited as stock drivers, while Veeva continues to expand its market-leading position in the life‑sciences sector. » More on finanzen.net

Veeva emphasized at the conference that about 98% of revenue still comes from the life sciences sector, commercial subscriptions recently showed roughly 13% year‑over‑year growth, and R&D growth has slowed to mid single‑digit to mid‑teens percentages. The newly positioned Falcon platform is intended to automate agent‑based end‑to‑end workflows, complemented by Vault AI for user‑centric productivity features; pricing for AI products will be transaction‑ and usage‑based to preserve software‑like margins. Veeva signals cautious but accelerated AI deployment, opportunistic acquisitions to speed the roadmap, and is launching Aspen as a standalone CRM initiative outside the core sector. » More on de.investing.com

Veeva Systems offers cloud software exclusively for the life‑sciences sector and is used by more than 1,500 pharmaceutical, biotech, and medical‑technology companies for clinical trials, regulatory approval, quality, drug safety, and marketing. Products such as Vault CRM, Development Cloud, Quality Cloud, and Data Cloud are deeply embedded in regulated workflows, creating high switching costs and a strong moat. Veeva is targeting a market share of over 70% and sees AI features as extending this competitive advantage. » More on finanzen.net